Pharmacological Treatments and Drug Development

Pharmacological treatments for neurodegenerative diseases, such as Alzheimer's and Parkinson's, have seen significant advancements. Current medications like donepezil and levodopa offer symptomatic relief, improving quality of life, though their efficacy varies and does not halt disease progression. The pipeline for drug development is promising, with emerging treatments such as anti-amyloid antibodies and novel neuroprotective agents showing potential in clinical trials. However, drug development faces challenges, including the complexity of neurodegenerative pathologies, difficulties in achieving targeted drug delivery, and high clinical trial failure rates. Continued research is essential to overcome these hurdles and develop effective, disease-modifying therapies.

    Related Conference of Pharmacological Treatments and Drug Development

    September 22-23, 2025

    6th Annual Congress on Psychiatry

    Paris, France
    October 27-28, 2025

    39th International Conference on Psychiatry and Mental Health

    Amsterdam, Netherlands
    November 10-11, 2025

    5th Annual Psychiatrists and Psychologists Meet

    Vancouver, Canada
    November 10-11, 2025

    International Congress on Cognitive Psychotherapy

    Vancouver, Canada
    November 24-25, 2025

    5thAnnual Congress on Mental Health & Psychiatry

    Barcelona, Spain
    February 16-16, 2026

    43rd Global Psychiatry and Mental Health Conference

    Paris, France
    February 16-17, 2026

    6th Annual Congress on Mental Health

    Paris, France
    April 20-21, 2026

    33rd World Psychiatrists and Psychologists Meet

    Rome, Italy
    May 27-28, 2026

    8th European Autism Congress

    Paris, France

    Pharmacological Treatments and Drug Development Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in